IQVIA (NYSE:IQV) Given New $210.00 Price Target at Robert W. Baird

IQVIA (NYSE:IQV) had its price objective reduced by equities researchers at Robert W. Baird from $212.00 to $210.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price target suggests a potential upside of 6.46% from the company’s previous close.

IQV has been the topic of several other research reports. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Bank of America decreased their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Redburn Atlantic began coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Stock Down 0.2 %

IQV opened at $197.25 on Tuesday. The company has a market cap of $35.80 billion, a PE ratio of 25.89, a price-to-earnings-growth ratio of 2.01 and a beta of 1.48. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a 50-day moving average price of $200.09 and a 200 day moving average price of $221.39. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in IQVIA during the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA during the third quarter worth about $28,000. Avior Wealth Management LLC boosted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in IQVIA by 74.4% during the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after buying an additional 99 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.